PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

MLA

Christine B. Peterson, et al. “PBRM1 Loss Defines a Nonimmunogenic Tumor Phenotype Associated with Checkpoint Inhibitor Resistance in Renal Carcinoma.” Nature Communications, vol. 11, May 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....169693e3a7a8721c7b30551fde62637b&authtype=sso&custid=ns315887.

APA

Christine B. Peterson, Truong Nguyen Anh Lam, Sevinj Isgandrova, Nizar M. Tannir, Eric Jonasch, Xian De Liu, Anh Hoang, Wen Kong, Nidhi Sahni, Daniel J. McGrail, Haifeng Zhu, Margarita Martinez-Moczygemba, Kathryn E. Beckermann, W. Kimryn Rathmell, Shiaw Yih Lin, Patrick G. Pilie, Xuesong Zhang, & Scott M. Haake. (2020). PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature Communications, 11.

Chicago

Christine B. Peterson, Truong Nguyen Anh Lam, Sevinj Isgandrova, Nizar M. Tannir, Eric Jonasch, Xian De Liu, Anh Hoang, et al. 2020. “PBRM1 Loss Defines a Nonimmunogenic Tumor Phenotype Associated with Checkpoint Inhibitor Resistance in Renal Carcinoma.” Nature Communications 11 (May). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....169693e3a7a8721c7b30551fde62637b&authtype=sso&custid=ns315887.